nach oben

Erschienen in:

23.11.2023 | Original Communication

Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium

verfasst von: Dejan Jakimovski, Katelyn S. Kavak, Patricia K. Coyle, Andrew D. Goodman, Malcolm Gottesman, Robert Zivadinov, Bianca Weinstock-Guttman, the New York State Multiple Sclerosis Consortium (NYSMSC)

Erschienen in: Journal of Neurology | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

The impact of disease-modifying treatments (DMTs) on multiple sclerosis (MS) long-term outcomes is continuously evolving. Retrospective analyses of large and long-term registries could provide information regarding general disease trajectories and risk factors that are commonly not investigated in shorter clinical trial settings.

Methods

Retrospective observational study of people with MS (pwMS) registered in New York State MS Consortium (NYSMSC) since 1996. Disability outcomes of reaching sustained Expanded Disability Status Scale (EDSS) scores of 4.0, 6.0 and transition to secondary-progressive MS (SPMS) were confirmed at follow-up. Four DMT categories were determined (1) continuous DMT use, (2) discontinued DMT, (3) (re)started DMT and (4) never treated with DMT. Patient-reported outcomes (PRO) were acquired using LIFEware system. Kaplan–Meier survival curves and adjusted analysis of covariance (ANCOVA) were used to determine the rate and factors related to disability progression.

Results

Total of 1893 pwMS were included with baseline average age of 43.2 years (SD = 10.4), 9.6 years of disease duration (SD = 8.8), median EDSS of 3.0 (IQR 2.0–3.5) and average follow-up time of 6.9 years (SD = 4.9). In addition to being male, older, more disabled and reporting worse PROs at baseline, pwMS who discontinued DMT had more than 5.5 times greater risk of reaching sustained EDSS of 4.0 (OR = 5.56, 95% CI 2.78–11.0, p < 0.001). Similarly, pwMS who discontinued DMT during the NYSMSC follow-up had 3.8- and 4.7-times greater risk to reach sustained EDSS 6.0 (OR = 3.86, 95% CI 2.12–7.02, p < 0.001), and to transition to SPMS (OR = 4.77, 95% CI 2.9–7.87, p < 0.001). Propensity matching analysis confirmed the worse clinical outcomes.

Conclusions

In addition to known predictors of long-term clinical outcomes, pwMS who discontinue DMT have worse long-term disability trajectory when compared to both early and late DMT starters. PRO-based indicators may suggest worse clinical outcomes.

Nur mit Berechtigung zugänglich

Collaborators GBDMS (2019) Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18:269–285CrossRef

Confavreux C, Vukusic S (2006) Age at disability milestones in multiple sclerosis. Brain 129:595–605CrossRefPubMed

Confavreux C, Vukusic S (2006) Natural history of multiple sclerosis: a unifying concept. Brain 129:606–616CrossRefPubMed

Corboy JR, Fox RJ, Kister I, Cutter GR, Morgan CJ, Seale R, Engebretson E, Gustafson T, Miller AE, Investigators D (2023) Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial. Lancet Neurol 22:568–577CrossRefPubMed

Cree BA, Gourraud PA, Oksenberg JR, Bevan C, Crabtree-Hartman E, Gelfand JM, Goodin DS, Graves J, Green AJ, Mowry E, Okuda DT, Pelletier D, von Büdingen HC, Zamvil SS, Agrawal A, Caillier S, Ciocca C, Gomez R, Kanner R, Lincoln R, Lizee A, Qualley P, Santaniello A, Suleiman L, Bucci M, Panara V, Papinutto N, Stern WA, Zhu AH, Cutter GR, Baranzini S, Henry RG, Hauser SL (2016) Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol 80:499–510CrossRefPubMedPubMedCentral

Granger C (1999) The LIFEware system. J Rehabil Outcomes Meas 3:63–69

Hartung HP, Graf J, Kremer D (2020) Long-term follow-up of multiple sclerosis studies and outcomes from early treatment of clinically isolated syndrome in the BENEFIT 11 study. J Neurol 267:308–316CrossRefPubMed

Healy BC, Zurawski J, Chitnis T, Weiner HL, Glanz BI (2022) Patient-reported outcomes associated with transition to secondary progressive multiple sclerosis. Qual Life Res 31:1799–1805CrossRefPubMed

Inojosa H, Proschmann U, Akgun K, Ziemssen T (2021) A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition. J Neurol 268:1210–1221CrossRefPubMed

10.

Jakimovski D, Eckert SP, Zivadinov R, Weinstock-Guttman B (2021) Considering patient age when treating multiple sclerosis across the adult lifespan. Expert Rev Neurother 21:353–364CrossRefPubMed

11.

Jakimovski D, Kavak KS, Vaughn CB, Goodman AD, Coyle PK, Krupp L, Gottesman M, Edwards KR, Lenihan M, Perel A, Zivadinov R, Weinstock-Guttman B (2022) Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age. Multiple Scler Relat Disord 57:103406CrossRef

12.

Jakimovski D, Kavak KS, Zakalik K, Coetzee T, Gottesman M, Coyle PK, Zivadinov R, Weinstock-Guttman B (2022) Improvement in time to multiple sclerosis diagnosis: 25-year retrospective analysis from New York State MS Consortium (NYSMSC). Multiple Scler J 29:753–756CrossRef

13.

Jakimovski D, Bittner S, Zivadinov R, Morrow SA, Benedict RHB, Zipp F, Weinstock-Guttman (2023) Multiple sclerosis. The Lancet

14.

Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrink R, Suarez G, Wicklein EM (2016) The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology 87:978–987CrossRefPubMedPubMedCentral

15.

Kister I, Spelman T, Alroughani R, Lechner-Scott J, Duquette P, Grand’Maison F, Slee M, Lugaresi A, Barnett M, Grammond P, Iuliano G, Hupperts R, Pucci E, Trojano M, Butzkueven H (2016) Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. J Neurol Neurosurg Psychiatry 87:1133–1137CrossRefPubMed

16.

Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452CrossRefPubMed

17.

Lorscheider J, Buzzard K, Jokubaitis V, Spelman T, Havrdova E, Horakova D, Trojano M, Izquierdo G, Girard M, Duquette P, Prat A, Lugaresi A, Grand’Maison F, Grammond P, Hupperts R, Alroughani R, Sola P, Boz C, Pucci E, Lechner-Scott J, Bergamaschi R, Oreja-Guevara C, Iuliano G, Van Pesch V, Granella F, Ramo-Tello C, Spitaleri D, Petersen T, Slee M, Verheul F, Ampapa R, Amato MP, McCombe P, Vucic S, Sanchez Menoyo JL, Cristiano E, Barnett MH, Hodgkinson S, Olascoaga J, Saladino ML, Gray O, Shaw C, Moore F, Butzkueven H, Kalincik T, Group MSS (2016) Defining secondary progressive multiple sclerosis. Brain 139:2395–2405CrossRefPubMed

18.

Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B Jr, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O’Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH (2014) Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83:278–286CrossRefPubMedPubMedCentral

19.

Manouchehrinia A, Zhu F, Piani-Meier D, Lange M, Silva DG, Carruthers R, Glaser A, Kingwell E, Tremlett H, Hillert J (2019) Predicting risk of secondary progression in multiple sclerosis: a nomogram. Multiple Scler 25:1102–1112CrossRef

20.

McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121–127CrossRefPubMed

21.

Miller AE, Vermersch P, Kappos L, Comi G, Freedman MS, Oh J, de Seze J, Truffinet P, Benamor M, Purvis A, Wolinsky JS (2019) Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: results of the TOPIC extension study^★★. Multiple Scler Relat Disord 33:131–138CrossRef

22.

Motl RW, Cohen JA, Benedict R, Phillips G, LaRocca N, Hudson LD, Rudick R (2017) Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis. Mult Scler 23:704–710CrossRefPubMedPubMedCentral

23.

Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292–302CrossRefPubMedPubMedCentral

24.

Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O’Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria.” Ann Neurol 58:840–846CrossRefPubMed

25.

Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227–231CrossRefPubMed

26.

Salas M, Hofman A, Stricker BH (1999) Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol 149:981–983CrossRefPubMed

27.

Simmons SB, Schippling S, Giovannoni G, Ontaneda D (2021) Predicting disability worsening in relapsing and progressive multiple sclerosis. Curr Opin Neurol 34:312–321CrossRefPubMed

28.

Sorensen PS, Sellebjerg F, Hartung HP, Montalban X, Comi G, Tintoré M (2020) The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history. Brain 143:2637–2652CrossRefPubMed

29.

Sormani MP (2009) The Will Rogers phenomenon: the effect of different diagnostic criteria. J Neurol Sci 287(Suppl 1):S46-49CrossRefPubMed

30.

Tedeholm H, Skoog B, Lisovskaja V, Runmarker B, Nerman O, Andersen O (2015) The outcome spectrum of multiple sclerosis: disability, mortality, and a cluster of predictors from onset. J Neurol 262:1148–1163CrossRefPubMed

31.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintore M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162–173CrossRefPubMed

32.

Tintore M, Cobo-Calvo A, Carbonell P, Arrambide G, Otero-Romero S, Río J, Tur C, Comabella M, Nos C, Arévalo MJ, Midaglia L, Galán I, Vidal-Jordana A, Castilló J, Rodríguez-Acevedo B, Zabalza de Torres A, Salerno A, Auger C, Sastre-Garriga J, Rovira À, Montalban X (2021) Effect of changes in MS diagnostic criteria over 25 years on time to treatment and prognosis in patients with clinically isolated syndrome. Neurology 97:e1641–e1652CrossRefPubMed

33.

Tremlett H, Yinshan Z, Devonshire V (2008) Natural history of secondary-progressive multiple sclerosis. Mult Scler 14:314–324CrossRefPubMed

34.

Trojano M, Pellegrini F, Fuiani A, Paolicelli D, Zipoli V, Zimatore GB, Di Monte E, Portaccio E, Lepore V, Livrea P, Amato MP (2007) New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol 61:300–306CrossRefPubMed

35.

Vaughn C, Kavak KS, Jakimovski D, Qutab N, Avila R, Vignos M, Weinstock-Guttman B (2023) Patient-reported outcomes are the strongest predictors of disease disability in intramuscular interferon beta-1a users. Neurodegener Dis Manag 13:151–159CrossRefPubMed

36.

Vaughn CB, Jakimovski D, Kavak KS, Ramanathan M, Benedict RHB, Zivadinov R, Weinstock-Guttman B (2019) Epidemiology and treatment of multiple sclerosis in elderly populations. Nat Rev Neurol 15:329–342CrossRefPubMed

37.

Vaughn CB, Kavak KS, Dwyer MG, Bushra A, Nadeem M, Cookfair DL, Ramanathan M, Benedict RHB, Zivadinov R, Goodman A, Krupp L, Motl RW, Weinstock-Guttman B, Kolb C, Robb JF, Jubelt B, Gerber A, Kister I, Ryerson LZ, Coyle P, Perel A, Gottesman M, Lenihan M, Edwards K, Garten L, Picone MA (2018) Fatigue at enrollment predicts EDSS worsening in the New York State Multiple Sclerosis Consortium. Mult Scler J 26:99–108CrossRef

38.

Zhang Y, Gonzalez Caldito N, Shirani A, Salter A, Cutter G, Culpepper W, Wallin M, Kosa P, Bielekova B, Lublin F, Stuve O (2020) Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials. Ther Adv Neurol Disord 13:1756286420969016CrossRefPubMedPubMedCentral

39.

Zivadinov R, Cookfair DL, Krupp L, Miller AE, Lava N, Coyle PK, Goodman AD, Jubelt B, Lenihan M, Herbert J, Gottesman M, Snyder DH, Apatoff BR, Teter BE, Perel AB, Munschauer F, Weinstock-Guttman B (2016) Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC). BMC Neurol 16:102CrossRefPubMedPubMedCentral

Titel: Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium
verfasst von: Dejan Jakimovski
Katelyn S. Kavak
Patricia K. Coyle
Andrew D. Goodman
Malcolm Gottesman
Robert Zivadinov
Bianca Weinstock-Guttman
the New York State Multiple Sclerosis Consortium (NYSMSC)
Publikationsdatum: 23.11.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Neurology / Ausgabe 2/2024
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-023-12099-x

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2024

Implementation of a 7T Epilepsy Task Force consensus imaging protocol for routine presurgical epilepsy work-up: effect on diagnostic yield and lesion delineation

Case report of palatal tremor as a feature of CASPR2 autoimmune encephalitis

Neurosarcoidosis

Mitochondrial myopathy without extraocular muscle involvement: a unique clinicopathologic profile

Genetic testing in adults with neurologic disorders: indications, approach, and clinical impacts